Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial
Author(s) -
Katherine Theiss-Nyland,
Mila Shakya,
Rachel Colin-Jones,
Merryn Voysey,
Nicola Smith,
Abhilasha Karkey,
Sabina Dongol,
Dikshya Pant,
Yama F Mujadidi,
Kathleen M. Neuzil,
Shrijana Shrestha,
Buddha Basnyat,
Andrew J. Pollard
Publication year - 2019
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciy1106
Subject(s) - medicine , typhoid fever , randomized controlled trial , environmental health , sanitation , conjugate vaccine , population , public health , vaccination , pediatrics , immunization , immunology , virology , nursing , antigen , pathology
Enteric fever is estimated to affect 11-20 million people worldwide each year. Morbidity and mortality from enteric fever primarily occur in lower-income countries, with children under 5 years of age experiencing a significant portion of the burden. Over the last few decades, the control of enteric fever has focused primarily on improved water and sanitation, with the available vaccines unsuitable for children and primarily used by travelers. A new typhoid conjugate vaccine (Vi-TCV), prequalified by the World Health Organization (WHO) and highly immunogenic in children under 5, has the potential to reduce the typhoid burden in endemic countries.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom